JP2020526196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526196A5 JP2020526196A5 JP2019572719A JP2019572719A JP2020526196A5 JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5 JP 2019572719 A JP2019572719 A JP 2019572719A JP 2019572719 A JP2019572719 A JP 2019572719A JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- glycan
- ornithine
- putrescine
- glycans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 32
- 108090000288 Glycoproteins Proteins 0.000 claims 32
- 238000000034 method Methods 0.000 claims 23
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 22
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 12
- 229960003104 ornithine Drugs 0.000 claims 12
- 235000010469 Glycine max Nutrition 0.000 claims 11
- 244000068988 Glycine max Species 0.000 claims 11
- 239000005700 Putrescine Substances 0.000 claims 11
- 241000894007 species Species 0.000 claims 7
- 108010081667 aflibercept Proteins 0.000 claims 6
- 229960002833 aflibercept Drugs 0.000 claims 6
- 108010046141 rilonacept Proteins 0.000 claims 6
- 229960001886 rilonacept Drugs 0.000 claims 6
- 108010008165 Etanercept Proteins 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 229960000403 etanercept Drugs 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 4
- 239000006143 cell culture medium Substances 0.000 claims 3
- 102000035122 glycosylated proteins Human genes 0.000 claims 3
- 108091005608 glycosylated proteins Proteins 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021111482A JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529471P | 2017-07-06 | 2017-07-06 | |
| US62/529,471 | 2017-07-06 | ||
| US201862625744P | 2018-02-02 | 2018-02-02 | |
| US62/625,744 | 2018-02-02 | ||
| PCT/US2018/040734 WO2019010191A1 (en) | 2017-07-06 | 2018-07-03 | CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Division JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Division JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526196A JP2020526196A (ja) | 2020-08-31 |
| JP2020526196A5 true JP2020526196A5 (https=) | 2021-08-12 |
| JP7265494B2 JP7265494B2 (ja) | 2023-04-26 |
Family
ID=64904487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572719A Active JP7265494B2 (ja) | 2017-07-06 | 2018-07-03 | 糖タンパク質を作製するための細胞培養方法 |
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20190010531A1 (https=) |
| EP (2) | EP3967765A1 (https=) |
| JP (5) | JP7265494B2 (https=) |
| KR (4) | KR102659791B1 (https=) |
| CN (3) | CN118878651A (https=) |
| AU (4) | AU2018298039B2 (https=) |
| BR (1) | BR112020000127A2 (https=) |
| CA (1) | CA3067847A1 (https=) |
| IL (2) | IL326217A (https=) |
| MX (2) | MX2020000228A (https=) |
| SG (1) | SG11201912548XA (https=) |
| TW (2) | TWI910092B (https=) |
| WO (1) | WO2019010191A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| CA3066918A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US10961500B1 (en) * | 2019-04-23 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Cell culture medium for eukaryotic cells |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN113679744B (zh) * | 2020-05-18 | 2023-12-29 | 中国人民解放军军事科学院军事医学研究院 | 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途 |
| CN114058673A (zh) * | 2021-09-15 | 2022-02-18 | 江苏先思达生物科技有限公司 | 一种脂肪肝检测试剂及其在脂肪肝检测中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE194384T1 (de) | 1989-09-12 | 2000-07-15 | Hoffmann La Roche | Tnf-bindende proteine |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1365660B1 (en) * | 2001-03-05 | 2007-09-12 | Council of Scientific and Industrial Research | Process for preparation of protein-hydrolysate from soy flour |
| SG106672A1 (en) | 2002-03-08 | 2004-10-29 | Asml Netherlands Bv | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| KR100897379B1 (ko) | 2004-06-08 | 2009-05-14 | 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 | 혈관신생-저해 키메릭 단백질 및 그 사용 |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| US7642078B2 (en) * | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
| EP3653699A1 (en) * | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| WO2008154014A2 (en) * | 2007-06-11 | 2008-12-18 | Amgen Inc. | A method for culturing mammalian cells to improve recombinant protein production |
| NZ583019A (en) | 2007-07-31 | 2011-05-27 | Regeneron Pharma | Human antibodies to human cd20 and method of using thereof |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN101603026B (zh) * | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| CN104962539B (zh) * | 2009-07-31 | 2019-09-17 | 百深公司 | 用于adamts蛋白表达的细胞培养基 |
| CN102115728B (zh) * | 2009-12-31 | 2012-09-26 | 北京清大天一科技有限公司 | 无血清动物细胞培养基干粉、液体培养基及其制备方法 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| EP2611904A2 (en) * | 2010-08-31 | 2013-07-10 | Friesland Brands B.V. | Culture medium for eukaryotic cells |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| BR112013008366B1 (pt) | 2010-10-06 | 2022-02-08 | Regeneron Pharmaceuticals, Inc | Formulações farmacêuticas líquidas estáveis contendo anticorpos anti-receptor de interleucina-4 humana alfa, e recipiente contendo as referidas formulações |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| US20140286946A1 (en) * | 2011-10-31 | 2014-09-25 | Merck Sharp & Dohme Corp. | Method for preparing antibodies having improved properties |
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| AU2013212587B2 (en) | 2012-01-23 | 2017-07-20 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-Ang2 antibodies |
| WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| DK3103861T3 (da) * | 2012-06-21 | 2020-11-16 | Baxalta GmbH | Virusfiltrering af cellekulturmedier |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| UY34962A (es) * | 2012-08-02 | 2014-02-28 | Sanofi Sa | Articulo de fabricacion que comprende aflibercept o ziv-aflibercept. |
| TWI596115B (zh) | 2012-08-13 | 2017-08-21 | 再生元醫藥公司 | 具有ｐＨ－依賴性結合特性之抗－ＰＣＳＫ９抗體 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| WO2014152195A1 (en) | 2013-03-15 | 2014-09-25 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| US20160237400A1 (en) * | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| EP3004368B1 (en) * | 2013-05-29 | 2019-09-18 | F.Hoffmann-La Roche Ag | Quantitative control of sialylation |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| EP3094735A1 (en) | 2014-01-13 | 2016-11-23 | Amgen Inc. | Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SG10202003996YA (en) | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| CA2950423A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| JP2017516484A (ja) * | 2014-06-03 | 2017-06-22 | ルピン・リミテッド | タンパク質生産のための細胞培養工程 |
| KR20170062466A (ko) | 2014-09-16 | 2017-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-글루카곤 항체 및 그것의 사용 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| TWI734775B (zh) * | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
-
2018
- 2018-07-03 KR KR1020207000732A patent/KR102659791B1/ko active Active
- 2018-07-03 CN CN202411053765.1A patent/CN118878651A/zh active Pending
- 2018-07-03 AU AU2018298039A patent/AU2018298039B2/en active Active
- 2018-07-03 IL IL326217A patent/IL326217A/en unknown
- 2018-07-03 TW TW107122944A patent/TWI910092B/zh active
- 2018-07-03 KR KR1020257008109A patent/KR20250041082A/ko active Pending
- 2018-07-03 CN CN201880045238.2A patent/CN110914293B/zh active Active
- 2018-07-03 EP EP21196848.2A patent/EP3967765A1/en active Pending
- 2018-07-03 EP EP18827553.1A patent/EP3649144A4/en active Pending
- 2018-07-03 KR KR1020217020548A patent/KR20210084695A/ko not_active Ceased
- 2018-07-03 CN CN202111031466.4A patent/CN114075269A/zh active Pending
- 2018-07-03 US US16/026,539 patent/US20190010531A1/en not_active Abandoned
- 2018-07-03 JP JP2019572719A patent/JP7265494B2/ja active Active
- 2018-07-03 BR BR112020000127-9A patent/BR112020000127A2/pt unknown
- 2018-07-03 CA CA3067847A patent/CA3067847A1/en active Pending
- 2018-07-03 KR KR1020247012715A patent/KR102782655B1/ko active Active
- 2018-07-03 SG SG11201912548XA patent/SG11201912548XA/en unknown
- 2018-07-03 TW TW114106933A patent/TW202526028A/zh unknown
- 2018-07-03 WO PCT/US2018/040734 patent/WO2019010191A1/en not_active Ceased
- 2018-07-03 MX MX2020000228A patent/MX2020000228A/es unknown
-
2019
- 2019-12-18 IL IL271524A patent/IL271524A/en unknown
-
2020
- 2020-01-08 MX MX2024013233A patent/MX2024013233A/es unknown
- 2020-01-14 US US16/742,723 patent/US20200131554A1/en not_active Abandoned
- 2020-05-01 US US16/864,689 patent/US20200255880A1/en not_active Abandoned
-
2021
- 2021-07-05 JP JP2021111482A patent/JP2021166537A/ja active Pending
- 2021-08-23 US US17/409,193 patent/US20210388408A1/en not_active Abandoned
- 2021-08-23 US US17/409,158 patent/US20210388407A1/en active Pending
- 2021-09-06 AU AU2021229121A patent/AU2021229121A1/en not_active Abandoned
-
2023
- 2023-01-18 JP JP2023005801A patent/JP7525672B2/ja active Active
- 2023-05-01 AU AU2023202659A patent/AU2023202659B2/en active Active
-
2024
- 2024-07-18 JP JP2024114751A patent/JP7736872B2/ja active Active
-
2025
- 2025-04-30 AU AU2025203053A patent/AU2025203053A1/en active Pending
- 2025-08-28 JP JP2025142351A patent/JP2025172879A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020526196A5 (https=) | ||
| Hirahara et al. | Helper T‐cell differentiation and plasticity: insights from epigenetics | |
| Lacruz et al. | Identification of novel candidate genes involved in mineralization of dental enamel by genome‐wide transcript profiling | |
| JP2018141797A5 (https=) | ||
| Zou et al. | Vulture genomes reveal molecular adaptations underlying obligate scavenging and low levels of genetic diversity | |
| ATE462000T1 (de) | Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin | |
| RU2010108308A (ru) | Способ получения гетерогенных белков | |
| JP2009055921A5 (https=) | ||
| RU2008126743A (ru) | Способ получения фармацевтической композиции | |
| JP2006500907A5 (https=) | ||
| BRPI0612273B8 (pt) | anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição | |
| EA200970263A1 (ru) | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков | |
| RU2013152816A (ru) | АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА | |
| Yamamoto et al. | Does genetic predisposition contribute to the exacerbation of COVID-19 symptoms in individuals with comorbidities and explain the huge mortality disparity between the East and the West? | |
| JPWO2020072821A5 (https=) | ||
| RU2017105260A (ru) | Фермент лизосомальной болезни накопления | |
| RU2011142793A (ru) | Полученная из микроорганизма протеаза усовершенствованного типа, обеспечивающая свертывание молока | |
| JP2005502319A5 (https=) | ||
| WO2024015875A3 (en) | Determination of protein information by recoding amino acid polymers into dna polymers | |
| Hayduk et al. | Cytochalasin D can improve heterologous protein productivity in adherent Chinese hamster ovary cells | |
| ATE502305T1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| RU2017134418A (ru) | Выявление аффинно-зрелых человеческих антител | |
| JP2010538089A5 (https=) | ||
| EA200600554A1 (ru) | Способ получения рекомбинантных белков | |
| Bruel et al. | Epithelial induction of porcine suppressor of cytokine signaling 2 (SOCS2) gene expression in response to Entamoeba histolytica |